Currently, two trending injectable GLP-1 receptor agonists are available for the treatment of obesity, including Wegovy (semaglutide) and Zepbound (tirzepatide)
This comprehensive approach aims to improve weight loss outcomes, addressing the needs of the estimated 12 million individuals in the UK who qualify for GLP-1 treatments
Regular exercise, a good diet, and proper sleep are among the basic ingredients for a sound mind (and body)
This process, known as paracrine signaling, allows exosomes to interact with cells in various ways - activating receptors on cell surfaces, merging with target cell membranes to release their cargo, or influencing the surrounding environment
Most patients find the discomfort minimal and manageable with repeated use